Login to Your Account

Durect to NASH-ville and beyond? 'Lucky' firm with metabolic NCE still in drug-delivery game

By Randy Osborne
Staff Writer

Tuesday, March 3, 2015

Durect Corp., better known as a drug delivery firm, disclosed a successful phase I trial with DUR-928, described as an endogenous small-molecule new chemical entity that could work in metabolic diseases such as nonalcoholic fatty liver disease and NASH.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription